A Phase 3 interventional study of Tirzepatide and Placebo in Obstructive Sleep Apnea and Obesity, sponsored by Eli Lilly and Company. Completed at 58 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-30.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 753 studies in Sleep Apnea, Obstructive with a site in United States — 126 open to participants now, 160 under way, 9 of them phase 3. Sleep Apnea, Obstructive · United States.
Among the 753 studies in Sleep Apnea, Obstructive with a site in United States, this one is the 32nd largest by enrollment of the 594 interventional ones that give a count, is one of 40 that started in 2022, is one of 39 in phase 3, and was the 581st registered.
2,243 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.
Browse Sleep Apnea, Obstructive studies →126 of the 753 studies in Sleep Apnea, Obstructive with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Nevada Dental Sleep · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18–40 · Women only
Fisher and Paykel Healthcare · Sites in United States
Ages 22+
Brigham and Women's Hospital · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 313 Sleep Apnea, Obstructive studies recruiting now, 146 (47%) set no upper age limit and 124 (40%) stop at 75 or younger; 52 take children under 18; 65 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
753 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 85 · Phase 3 45 · Phase 4 36
First in 1999; this study’s year is marked. 40 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 469 is above the median of 52 across 1,474 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 49 across the 594 interventional studies, 81 across the 157 observational. Of the 512 that completed or were terminated, 257 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
192 of 753 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 4 studies filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
65 of the studies in Sleep Apnea, Obstructive with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
| NCT04814420Tulane UniversityAtrial Fibrosis in Obstructive Sleep Apnea Patients: A Pilot Study | 2026-11 |
| NCT07103941Isabel Moreno HayIOA Preventing Occlusal Changes With MAD Use | 2026-11-28 |
| NCT01857427Ulysses Magalang MDA Prospective Observational Cohort to Study the Genetics of Obstructive Sleep Apnea and Associated Co-Morbidities | 2026-12 |
Add all 65 to your calendar (.ics) → With an account.
Among the 753 studies in Sleep Apnea, Obstructive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect and safety of tirzepatide in participants with moderate to severe obstructive sleep apnea and obesity who are both unwilling or unable to use Positive Airway Pressure (PAP) therapy in GPI1 and those who are and plan to stay on PAP therapy in GPI2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For GPI1 Participants:
For GPI2 Participants:
For Both GPI1 and GPI2 Participants:
Exclusion Criteria:
For GPI2 Participants:
For GPI1 and GPI2 Participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants not on positive airway pressure (PAP) therapy received a maximum tolerated dose (MTD) of 10 milligrams (mg) or 15 mg of Tirzepatide once weekly (QW) as a subcutaneous (SC) injection for 52 weeks, including the initial dose escalation by 2.5 mg every 4 weeks
Drug: Tirzepatide
Participants not on PAP therapy received placebo QW as an SC injection for 52 weeks.
Drug: Placebo
Participants who are on PAP therapy received an MTD of 10 mg or 15 mg of Tirzepatide QW as an SC injection for 52 weeks, including the initial dose escalation by 2.5 mg every 4 weeks
Drug: Tirzepatide
Participants who are on PAP therapy received placebo QW as an SC injection for 52 weeks.
Drug: Placebo
Administered SC
Also known as: LY3298176
Administered SC
Change From Baseline in Apnea-Hypopnea Index (AHI)
AHI, Apnea-Hypopnea Index, is the number of apneas or hypopneas recorded via polysomnography during the study per hour of sleep. Apnea is defined as a cessation of airflow lasting at least 10 seconds, hypopnea as a decrease in airflow by at least 30% from baseline for at least 10 seconds occurring with a drop in oxygen saturation (SpO₂) by at least 4%. AHI values are categorized as 5-15 events/hr = mild; 15-\<30 events/hr = moderate; and ≥ 30 events/hr = severe. a significant reduction in values indicates a positive outcome.
Time frame: Baseline, Week 52
Percent Change From Baseline in Apnea-Hypopnea Index (AHI)
Percent Change From Baseline in AHI was evaluated.
Time frame: Baseline, Week 52
Percentage of Participants With ≥50% AHI Reduction From Baseline
Percentage of participants achieving ≥50% AHI reduction from baseline to Week 52 was evaluated.
Time frame: Week 52
Percentage of Participants With AHI <5 or With AHI 5-14 With Epworth Sleepiness Scale (ESS) ≤10
The percentage of participants with OSA remission (AHI \<5 events per hour of sleep) or with mild OSA without excessive daytime sleepiness (AHI 5-14 events per hour of sleep with ESS ≤10) at Week 52 was evaluated. The ESS is used to assess improvements in excessive daytime sleepiness from baseline to Week 52. The ESS is an 8-item, participant-completed measure that asks the participant to rate, on a scale of 0 (no chance of dozing) to 3 (high chance of dozing), their usual chances of dozing in 8 different daytime situations, with a recall period of "in recent times." The ESS total score is the sum of the 8-item scores and ranges from 0 to 24, with higher scores indicating greater daytime sleepiness.
Time frame: Week 52
Change From Baseline in Sleep Apnea-Specific Hypoxic Burden (SASHB) (% Min/Hour)
SASHB was determined by measuring the respiratory event-associated area under the curve for oxygen desaturation from pre-event baseline and represents the cumulative burden of intermittent hypoxia caused by OSA-related sleep-disordered breathing at sleep.
Time frame: Baseline, Week 52
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form Sleep-Related Impairment 8a (PROMIS SRI) and PROMIS Short Form Sleep Disturbance 8b (PROMIS SD)
PROMIS SRI consists of 8 items that assess self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and perceived functional impairments associated with sleep problems. PROMIS SRI has a recall period of "in the past 7 days" and each item is rated on a 5-point scale from "not at all" to "very much." PROMIS SD consists of 8 items that assess self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. PROMIS SD has a recall period of "in the past 7 days" and each item is rated on a 5-point scale ranging from "not at all" to "very much," "never" to "always," or "very poor" to "very good." For both PROMIS SRI and PROMIS SD, item responses are used to generate T-scores which are standardized scores with a mean of 50 and a standard deviation of 10 (score range cannot be specified for T-scores). Higher T-scores indicate worse outcomes; more sleep-related impairment (PROMIS SRI) or more sleep disturbance (PROMIS SD).
Time frame: Baseline, Week 52
Percent Change From Baseline in Body Weight
Percent Change from Baseline in Body Weight was evaluated.
Time frame: Baseline, Week 52
Change From Baseline in High Sensitivity C Reactive Protein (hsCRP) Concentration
HsCRP is a marker for inflammation and was measured from blood samples to identify the presence of inflammation, to determine its severity, and to monitor response to treatment.
Time frame: Baseline, Week 52
Change From Baseline in Systolic Blood Pressure (SBP)
Change in systolic blood pressure from baseline to Week 48 was evaluated.
Time frame: Baseline, Week 48
NCT05412004 supports two pivotal studies: I8F-MC-GPI1 (GPI1; Study 1) and I8F-MC-GPI2 (GPI2; Study 2), conducted under the single master protocol I8F-MC-GPIF. The studies were conducted under a single overarching trial structure for operational efficiencies, but the study participants for both studies are different (GPI1 included participants who were unable or unwilling to use positive airway pressure (PAP) therapy, while GPI2 included those on PAP therapy).
| Milestone | Tirzepatide MTD_GPI1 | Placebo_GPI1 | Tirzepatide MTD_GPI2 | Placebo_GPI2 |
|---|---|---|---|---|
| Started | 114 | 120 | 120 | 115 |
| Received at least one dose of study drug | 114 | 120 | 119 | 114 |
| Completed | 101 | 86 | 113 | 89 |
| Not completed | 13 | 34 | 7 | 26 |
| Withdrew: Adverse event | 0 | 2 | 1 | 5 |
| Withdrew: Assigned treatment by mistake | 5 | 10 | 2 | 5 |
| Withdrew: Lost to follow-up | 3 | 0 | 0 | 0 |
| Withdrew: Patient could not travel to site | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 19 | 4 | 14 |
| Withdrew: Screen failure | 0 | 0 | 0 | 1 |
| Withdrew: The participant quit treatment and study due to their schedule and the final v801 was done remotely | 0 | 0 | 0 | 1 |
AHI, Apnea-Hypopnea Index, is the number of apneas or hypopneas recorded via polysomnography during the study per hour of sleep. Apnea is defined as a cessation of airflow lasting at least 10 seconds, hypopnea as a decrease in airflow by at least 30% from baseline for at least 10 seconds occurring with a drop in oxygen saturation (SpO₂) by at least 4%. AHI values are categorized as 5-15 events/hr = mild; 15-\<30 events/hr = moderate; and ≥ 30 events/hr = severe. a significant reduction in values indicates a positive outcome.
| events per hour | Tirzepatide MTD_GPI1 | Placebo_GPI1 | Tirzepatide MTD_GPI2 | Placebo_GPI2 |
|---|---|---|---|---|
| Change From Baseline in Apnea-Hypopnea Index (AHI) | -25.25 ± 2.06 | -5.25 ± 2.11 | -29.27 ± 1.99 | -5.51 ± 2.21 |
Percent Change From Baseline in AHI was evaluated.
| percentage change | Tirzepatide MTD_GPI1 | Placebo_GPI1 | Tirzepatide MTD_GPI2 | Placebo_GPI2 |
|---|---|---|---|---|
| Percent Change From Baseline in Apnea-Hypopnea Index (AHI) | -50.68 ± 5.90 | -3.03 ± 7.07 | -58.72 ± 5.28 | -2.50 ± 6.95 |
Percentage of participants achieving ≥50% AHI reduction from baseline to Week 52 was evaluated.
| percentage of participants | Tirzepatide MTD_GPI1 | Placebo_GPI1 | Tirzepatide MTD_GPI2 | Placebo_GPI2 |
|---|---|---|---|---|
| Percentage of Participants With ≥50% AHI Reduction From Baseline | 61.22 | 18.96 | 72.40 | 23.25 |
The percentage of participants with OSA remission (AHI \<5 events per hour of sleep) or with mild OSA without excessive daytime sleepiness (AHI 5-14 events per hour of sleep with ESS ≤10) at Week 52 was evaluated. The ESS is used to assess improvements in excessive daytime sleepiness from baseline to Week 52. The ESS is an 8-item, participant-completed measure that asks the participant to rate, on a scale of 0 (no chance of dozing) to 3 (high chance of dozing), their usual chances of dozing in 8 different daytime situations, with a recall period of "in recent times." The ESS total score is the sum of the 8-item scores and ranges from 0 to 24, with higher scores indicating greater daytime sleepiness.
| percentage of participants | Tirzepatide MTD_GPI1 | Placebo_GPI1 | Tirzepatide MTD_GPI2 | Placebo_GPI2 |
|---|---|---|---|---|
| Percentage of Participants With AHI <5 or With AHI 5-14 With Epworth Sleepiness Scale (ESS) ≤10 | 42.17 | 15.88 | 50.24 | 14.33 |
SASHB was determined by measuring the respiratory event-associated area under the curve for oxygen desaturation from pre-event baseline and represents the cumulative burden of intermittent hypoxia caused by OSA-related sleep-disordered breathing at sleep.
| %.min/hr | Tirzepatide MTD_GPI1 | Placebo_GPI1 | Tirzepatide MTD_GPI2 | Placebo_GPI2 |
|---|---|---|---|---|
| Change From Baseline in Sleep Apnea-Specific Hypoxic Burden (SASHB) (% Min/Hour) | -95.19 ± 4.081 | -25.07 ± 9.804 | -102.98 ± 3.758 | -41.69 ± 11.313 |
PROMIS SRI consists of 8 items that assess self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and perceived functional impairments associated with sleep problems. PROMIS SRI has a recall period of "in the past 7 days" and each item is rated on a 5-point scale from "not at all" to "very much." PROMIS SD consists of 8 items that assess self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. PROMIS SD has a recall period of "in the past 7 days" and each item is rated on a 5-point scale ranging from "not at all" to "very much," "never" to "always," or "very poor" to "very good." For both PROMIS SRI and PROMIS SD, item responses are used to generate T-scores which are standardized scores with a mean of 50 and a standard deviation of 10 (score range cannot be specified for T-scores). Higher T-scores indicate worse outcomes; more sleep-related impairment (PROMIS SRI) or more sleep disturbance (PROMIS SD).
| T score | Tirzepatide MTD_GPI1 | Placebo_GPI1 | Tirzepatide MTD_GPI2 | Placebo_GPI2 |
|---|---|---|---|---|
| Sleep Disturbance | -4.47 ± 0.69 | -2.44 ± 0.70 | -6.98 ± 0.82 | -3.08 ± 0.88 |
| Sleep-Related Impairment | -6.57 ± 0.83 | -3.13 ± 0.80 | -8.18 ± 0.95 | -3.91 ± 1.03 |
Percent Change from Baseline in Body Weight was evaluated.
| Percent change | Tirzepatide MTD_GPI1 | Placebo_GPI1 | Tirzepatide MTD_GPI2 | Placebo_GPI2 |
|---|---|---|---|---|
| Percent Change From Baseline in Body Weight | -17.65 ± 0.69 | -1.56 ± 0.68 | -19.62 ± 0.71 | -2.34 ± 0.74 |
HsCRP is a marker for inflammation and was measured from blood samples to identify the presence of inflammation, to determine its severity, and to monitor response to treatment.
| Milligram per liter (mg/L) | Tirzepatide MTD_GPI1 | Placebo_GPI1 | Tirzepatide MTD_GPI2 | Placebo_GPI2 |
|---|---|---|---|---|
| Change From Baseline in High Sensitivity C Reactive Protein (hsCRP) Concentration | -1.42 ± 0.151 | -0.70 ± 0.203 | -1.37 ± 0.130 | -0.33 ± 0.236 |
Change in systolic blood pressure from baseline to Week 48 was evaluated.
| Millimeters of mercury (mm Hg) | Tirzepatide MTD_GPI1 | Placebo_GPI1 | Tirzepatide MTD_GPI2 | Placebo_GPI2 |
|---|---|---|---|---|
| Change From Baseline in Systolic Blood Pressure (SBP) | -9.46 ± 1.02 | -1.84 ± 1.03 | -7.64 ± 1.03 | -3.94 ± 1.18 |
Collected over Baseline to Follow-up (Up To 56 Weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tirzepatide MTD_GPI1 | 0/114 (0%) | 9/114 (7.9%) | 91/114 (79.8%) |
| Placebo_GPI1 | 0/120 (0%) | 7/120 (5.8%) | 91/120 (75.8%) |
| Tirzepatide MTD_GPI2 | 0/119 (0%) | 7/119 (5.9%) | 98/119 (82.4%) |
| Placebo_GPI2 | 0/114 (0%) | 12/114 (10.5%) | 82/114 (71.9%) |
| Event | Tirzepatide MTD_GPI1 | Placebo_GPI1 | Tirzepatide MTD_GPI2 | Placebo_GPI2 |
|---|---|---|---|---|
| Abnormal uterine bleedingReproductive system and breast disorders | 0/36 | 0/41 | 0/32 | 1/32 |
| Suicide attemptPsychiatric disorders | 2/114 | 0/120 | 0/119 | 0/114 |
| Atrial fibrillationCardiac disorders | 0/114 | 2/120 | 1/119 | 0/114 |
| Prostate cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/78 | 0/79 | 0/87 | 1/82 |
| Acute myocardial infarctionCardiac disorders | 0/114 | 0/120 | 0/119 | 1/114 |
| Coronary artery diseaseCardiac disorders | 0/114 | 0/120 | 0/119 | 1/114 |
| DiarrhoeaGastrointestinal disorders | 1/114 | 0/120 | 1/119 | 0/114 |
| CholelithiasisHepatobiliary disorders | 0/114 | 1/120 | 0/119 | 1/114 |
| AppendicitisInfections and infestations | 1/114 | 0/120 | 0/119 | 0/114 |
| Dengue feverInfections and infestations | 0/114 | 0/120 | 1/119 | 1/114 |
| Event | Tirzepatide MTD_GPI1 | Placebo_GPI1 | Tirzepatide MTD_GPI2 | Placebo_GPI2 |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 30/114 | 15/120 | 26/119 | 10/114 |
| NauseaGastrointestinal disorders | 29/114 | 12/120 | 26/119 | 6/114 |
| VomitingGastrointestinal disorders | 20/114 | 5/120 | 11/119 | 1/114 |
| ConstipationGastrointestinal disorders | 18/114 | 3/120 | 18/119 | 5/114 |
| NasopharyngitisInfections and infestations | 3/114 | 8/120 | 15/119 | 12/114 |
| Covid-19Infections and infestations | 6/114 | 10/120 | 8/119 | 11/114 |
| DyspepsiaGastrointestinal disorders | 5/114 | 2/120 | 11/119 | 1/114 |
| EructationGastrointestinal disorders | 9/114 | 0/120 | 10/119 | 1/114 |
| Upper respiratory tract infectionInfections and infestations | 7/114 | 10/120 | 5/119 | 8/114 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 9/114 | 1/120 | 6/119 | 0/114 |
All randomized participants.
| Age, Customized(Participants) | Tirzepatide MTD_GPI1 | Placebo_GPI1 | Tirzepatide MTD_GPI2 | Placebo_GPI2 | Total |
|---|---|---|---|---|---|
| <50years | 63 | 62 | 54 | 45 | 224 |
| >=50years | 51 | 58 | 66 | 70 | 245 |
| Sex: Female, Male(Participants) | Tirzepatide MTD_GPI1 | Placebo_GPI1 | Tirzepatide MTD_GPI2 | Placebo_GPI2 | Total |
|---|---|---|---|---|---|
| Female | 36 | 41 | 33 | 32 | 142 |
| Male | 78 | 79 | 87 | 83 | 327 |
| Ethnicity (NIH/OMB)(Participants) | Tirzepatide MTD_GPI1 | Placebo_GPI1 | Tirzepatide MTD_GPI2 | Placebo_GPI2 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 51 | 47 | 38 | 38 | 174 |
| Not Hispanic or Latino | 63 | 69 | 82 | 76 | 290 |
| Unknown or Not Reported | 0 | 4 | 0 | 1 | 5 |
| Race (NIH/OMB)(Participants) | Tirzepatide MTD_GPI1 | Placebo_GPI1 | Tirzepatide MTD_GPI2 | Placebo_GPI2 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 9 | 9 | 10 | 9 | 37 |
| Asian | 23 | 24 | 17 | 16 | 80 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 7 | 8 | 3 | 24 |
| White | 74 | 80 | 85 | 86 | 325 |
| More than one race | 2 | 0 | 0 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Tirzepatide MTD_GPI1 | Placebo_GPI1 | Tirzepatide MTD_GPI2 | Placebo_GPI2 | Total |
|---|---|---|---|---|---|
| United States | 35 | 36 | 41 | 37 | 149 |
| China | 14 | 14 | 4 | 5 | 37 |
| Japan | 3 | 4 | 7 | 6 | 20 |
| Taiwan | 5 | 4 | 4 | 3 | 16 |
| Brazil | 24 | 25 | 18 | 17 | 84 |
| Mexico | 20 | 19 | 14 | 16 | 69 |
| Australia | 1 | 5 | 10 | 9 | 25 |
| Germany | 7 | 7 | 16 | 16 | 46 |
| Czechia | 5 | 6 | 6 | 6 | 23 |
| Baseline apnea-hypopnea index (AHI)(events per hour) | Tirzepatide MTD_GPI1 | Placebo_GPI1 | Tirzepatide MTD_GPI2 | Placebo_GPI2 | Total |
|---|---|---|---|---|---|
| Mean | 52.86 ± 30.50 | 50.13 ± 31.47 | 46.08 ± 22.35 | 53.10 ± 30.23 | 50.49 ± 28.98 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jun 2022 to primary completion in Mar 2024, 20 months.
Results were first posted in Apr 2025, 1 year 1 month after primary completion.
Of 27 phase 3 interventional studies under Sleep Apnea, Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 32. This study's 20 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide